Q3 2024 Earnings Estimate for Waters Co. (NYSE:WAT) Issued By Leerink Partnrs

Waters Co. (NYSE:WAT) – Equities researchers at Leerink Partnrs decreased their Q3 2024 earnings per share (EPS) estimates for shares of Waters in a note issued to investors on Thursday, July 18th. Leerink Partnrs analyst P. Souda now anticipates that the medical instruments supplier will earn $2.94 per share for the quarter, down from their previous estimate of $2.98. The consensus estimate for Waters’ current full-year earnings is $11.84 per share. Leerink Partnrs also issued estimates for Waters’ Q1 2025 earnings at $2.50 EPS, Q3 2025 earnings at $3.21 EPS and FY2025 earnings at $13.03 EPS.

A number of other equities research analysts have also commented on WAT. Robert W. Baird decreased their price objective on shares of Waters from $319.00 to $312.00 and set a “neutral” rating on the stock in a report on Wednesday, May 8th. Jefferies Financial Group began coverage on Waters in a research report on Monday, June 3rd. They issued a “hold” rating and a $320.00 price target on the stock. Barclays reduced their price objective on shares of Waters from $295.00 to $275.00 and set an “underweight” rating on the stock in a research note on Friday, June 28th. Stifel Nicolaus lifted their target price on Waters from $330.00 to $332.00 and gave the stock a “hold” rating in a report on Wednesday, May 8th. Finally, TD Cowen lifted their price target on shares of Waters from $350.00 to $358.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating and eleven have issued a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $301.20.

Waters Trading Down 2.1 %

WAT stock opened at $300.83 on Monday. Waters has a fifty-two week low of $231.90 and a fifty-two week high of $367.21. The stock has a market capitalization of $17.85 billion, a price-to-earnings ratio of 29.52, a P/E/G ratio of 4.82 and a beta of 0.95. The company has a debt-to-equity ratio of 1.60, a current ratio of 1.94 and a quick ratio of 1.30. The business has a fifty day moving average price of $307.74 and a 200 day moving average price of $320.84.

Waters (NYSE:WAT) last posted its earnings results on Tuesday, May 7th. The medical instruments supplier reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.10 by $0.11. The business had revenue of $636.80 million for the quarter, compared to analyst estimates of $635.57 million. Waters had a net margin of 20.75% and a return on equity of 66.59%. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.49 EPS.

Insider Buying and Selling

In other news, Director Richard H. Fearon bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was acquired at an average cost of $332.90 per share, with a total value of $332,900.00. Following the completion of the purchase, the director now owns 1,653 shares of the company’s stock, valued at $550,283.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Waters news, Director Richard H. Fearon purchased 1,000 shares of the stock in a transaction on Tuesday, May 28th. The shares were purchased at an average price of $332.90 per share, with a total value of $332,900.00. Following the completion of the transaction, the director now directly owns 1,653 shares in the company, valued at $550,283.70. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher A. Kuebler sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $361.64, for a total value of $1,446,560.00. Following the completion of the sale, the director now owns 14,716 shares in the company, valued at approximately $5,321,894.24. The disclosure for this sale can be found here. 0.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Waters

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WAT. Foguth Wealth Management LLC. acquired a new position in shares of Waters in the first quarter valued at approximately $2,773,000. Meridian Wealth Management LLC acquired a new stake in shares of Waters during the 4th quarter worth approximately $2,637,000. Raymond James & Associates increased its stake in shares of Waters by 295.9% in the 4th quarter. Raymond James & Associates now owns 127,879 shares of the medical instruments supplier’s stock valued at $42,102,000 after purchasing an additional 95,577 shares during the last quarter. Virtu Financial LLC bought a new position in Waters in the fourth quarter valued at about $962,000. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH grew its holdings in shares of Waters by 2,134.3% during the 1st quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 5,921 shares of the medical instruments supplier’s stock valued at $2,038,000 after purchasing an additional 5,656 shares during the last quarter. 94.01% of the stock is owned by institutional investors.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.